leukotriene B4 inhibitor (Eiger BioPharmaceuticals)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Nameleukotriene B4 inhibitor (Eiger BioPharmaceuticals)
Drug Alias Nameleukotriene B4 inhibitor (Eiger BioPharmaceuticals)leukotriene B4 inhibitor (Stanford University)
ClassificationSmall molecules
Mechanisms of ActionLeukotriene B4 modulators
TargetsLeukotriene B4
Therapy Area/IndicationsLymphedemaPulmonary Arterial Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesStanford University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEiger Biopharmaceuticals IncStanford University
Active IndicationsN/A
Inactive IndicationsLymphedemaPulmonary Arterial Hypertension

Other Information

ATC CodeN/A
Related LinksN/A